These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 25337673)

  • 21. Role of the receptor tyrosine kinase Axl in hepatocellular carcinoma and its clinical relevance.
    Niu ZS; Niu XJ; Wang WH
    Future Oncol; 2019 Feb; 15(6):653-662. PubMed ID: 30648886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
    Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
    Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation.
    Lauter M; Weber A; Torka R
    Cell Commun Signal; 2019 Jun; 17(1):59. PubMed ID: 31171001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.
    Nonagase Y; Takeda M; Azuma K; Hayashi H; Haratani K; Tanaka K; Yonesaka K; Ishii H; Hoshino T; Nakagawa K
    Thorac Cancer; 2019 Oct; 10(10):1928-1935. PubMed ID: 31419057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression.
    Goyette MA; Duhamel S; Aubert L; Pelletier A; Savage P; Thibault MP; Johnson RM; Carmeliet P; Basik M; Gaboury L; Muller WJ; Park M; Roux PP; Gratton JP; Côté JF
    Cell Rep; 2018 May; 23(5):1476-1490. PubMed ID: 29719259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Landscape of AXL Receptor Kinase in Triple-Negative Breast Cancer.
    Ozyurt R; Ozpolat B
    Mol Cancer Ther; 2023 Jul; 22(7):818-832. PubMed ID: 37028809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
    Taverna JA; Hung CN; DeArmond DT; Chen M; Lin CL; Osmulski PA; Gaczynska ME; Wang CM; Lucio ND; Chou CW; Chen CL; Nazarullah A; Lampkin SR; Qiu L; Bearss DJ; Warner S; Whatcott CJ; Mouritsen L; Wade M; Weitman S; Mesa RA; Kirma NB; Chao WT; Huang TH
    Cancer Res; 2020 Apr; 80(7):1551-1563. PubMed ID: 31992541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AXL Inhibitors: Status of Clinical Development.
    Bhalla S; Gerber DE
    Curr Oncol Rep; 2023 May; 25(5):521-529. PubMed ID: 36920638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Axl and Mer kinases in cancer.
    Verma A; Warner SL; Vankayalapati H; Bearss DJ; Sharma S
    Mol Cancer Ther; 2011 Oct; 10(10):1763-73. PubMed ID: 21933973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of the phenylpyrazolo[3,4-
    Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
    Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
    [No Abstract]   [Full Text] [Related]  

  • 31. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
    Byers LA; Diao L; Wang J; Saintigny P; Girard L; Peyton M; Shen L; Fan Y; Giri U; Tumula PK; Nilsson MB; Gudikote J; Tran H; Cardnell RJ; Bearss DJ; Warner SL; Foulks JM; Kanner SB; Gandhi V; Krett N; Rosen ST; Kim ES; Herbst RS; Blumenschein GR; Lee JJ; Lippman SM; Ang KK; Mills GB; Hong WK; Weinstein JN; Wistuba II; Coombes KR; Minna JD; Heymach JV
    Clin Cancer Res; 2013 Jan; 19(1):279-90. PubMed ID: 23091115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovering novel 7-azaindole-based series as potent AXL kinase inhibitors.
    Feneyrolles C; Guiet L; Singer M; Van Hijfte N; Daydé-Cazals B; Fauvel B; Chevé G; Yasri A
    Bioorg Med Chem Lett; 2017 Feb; 27(4):862-866. PubMed ID: 28094183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
    Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
    Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AXL-Driven EMT State as a Targetable Conduit in Cancer.
    Antony J; Huang RY
    Cancer Res; 2017 Jul; 77(14):3725-3732. PubMed ID: 28667075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling.
    Park JS; Lee C; Kim HK; Kim D; Son JB; Ko E; Cho JH; Kim ND; Nan HY; Kim CY; Yoon S; Lee SH; Choi HG
    Oncotarget; 2016 Dec; 7(50):83308-83318. PubMed ID: 27829217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bemcentinib and Gilteritinib Inhibit Cell Growth and Impair the Endo-Lysosomal and Autophagy Systems in an AXL-Independent Manner.
    Zdżalik-Bielecka D; Kozik K; Poświata A; Jastrzębski K; Jakubik M; Miączyńska M
    Mol Cancer Res; 2022 Mar; 20(3):446-455. PubMed ID: 34782372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
    Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
    Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs.
    Wilson C; Ye X; Pham T; Lin E; Chan S; McNamara E; Neve RM; Belmont L; Koeppen H; Yauch RL; Ashkenazi A; Settleman J
    Cancer Res; 2014 Oct; 74(20):5878-90. PubMed ID: 25125659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma.
    Fleuren ED; Hillebrandt-Roeffen MH; Flucke UE; Te Loo DM; Boerman OC; van der Graaf WT; Versleijen-Jonkers YM
    Oncotarget; 2014 Dec; 5(24):12753-68. PubMed ID: 25528764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH.
    Grøndal SM; Tutusaus A; Boix L; Reig M; Blø M; Hodneland L; Gausdal G; Jackson A; Garcia de Frutos P; Lorens JB; Morales A; Marí M
    Front Immunol; 2024; 15():1400553. PubMed ID: 38817615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.